Vir backs cross-reactive mAb strategy with preclinical potency data

Vir has reported preclinical potency for a mAb against SARS-CoV-2 that beats the potencies other anti-SARS-CoV-2 mAbs recently reported and is on par with the company’s clinically validated Ebola therapy.

The mAb, dubbed S309, was isolated from a SARS patient and cross-neutralizes SARS-CoV and SARS-CoV-2. Vir’s first two clinical candidates for COVID-19, VIR-7831 and VIR-7832, are based on S309. ...